Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Sintilimab will be administered by IV, 200 mg every 3 weeks

Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 weeks.

Camrelizumab will be administered by IV, 200 mg every 2 weeks.

Rivoceranib will be administered by oral 250 mg once daily.

Nivolumab will be administered by IV, 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks

Ipilimumab will be administered by IV, 3mg/kg every 3 weeks for up to four doses.